BPC-157 is a synthetic pentadecapeptide — a 15-amino acid fragment — derived from a naturally occurring protein isolated in human gastric juice. It is one of the most extensively studied tissue repair peptides in preclinical literature, with over 30 years of published research examining its effects on musculoskeletal tissues, the gastrointestinal system, vascular biology, and the central nervous system.
BPC-157 exerts its effects through several interconnected molecular pathways. Central among these is upregulation of the VEGFR2 receptor, which drives proangiogenic activity — the formation of new blood vessels — in injured tissues. New vascular supply is a rate-limiting step in tissue repair, and BPC-157's consistent stimulation of this pathway across multiple tissue types may account for much of its observed activity in preclinical animal models.
BPC-157 also activates the FAK-paxillin signalling axis and the JAK2/STAT3 pathway, both of which regulate fibroblast migration, proliferation, and extracellular matrix synthesis — processes studied in preclinical tendon, ligament, and muscle injury models. In tendon fibroblast culture experiments, BPC-157 dose-dependently increased growth hormone receptor expression, which when combined with exogenous growth hormone, enhanced both cell proliferation and JAK2 phosphorylation.
The peptide also modulates nitric oxide (NO) synthesis and demonstrates cytoprotective and anti-inflammatory properties — suppressing pro-inflammatory cytokines such as TNF-α while preserving tissue integrity in models of chemically or surgically induced injury. Its exceptional acid stability means it retains bioactivity after oral administration, an unusual property among peptides of its class.
BPC-157 was first characterised in the context of gastrointestinal biology, where it has been studied for cytoprotective activity in gastric and intestinal mucosa models. It has been studied in models of gastric lesions induced by stress, NSAIDs, ethanol, and cysteamine, with observed differences in mucosal integrity in preclinical study conditions.
Its acid stability makes it unique among bioactive peptides — BPC-157 is not readily degraded by stomach acid. The peptide has also been investigated in inflammatory bowel disease models, where anti-inflammatory signalling and mucosal integrity markers have been studied in rodent models.
A 2025 systematic review (SAGE Journals) analysed 36 published studies from 1993–2024. BPC-157 enhanced growth hormone receptor expression and angiogenic pathways while reducing inflammatory cytokines across preclinical models. Differences in outcome measures were reported across preclinical muscle, tendon, ligament, and bone injury models.
In Achilles tendon repair models, healed tendons in BPC-157-treated groups showed increased load-to-failure tensile strength and higher functional scores on the Achilles Functional Index over 14-day periods.
BPC-157 has been studied in models of CNS injury, demonstrating interactions with the dopaminergic and serotonergic systems, anxiolytic-adjacent signalling and nociception pathway modulation in rodent models. A 2024 PMC review documented its possible role as a neurotransmitter-modulating cytoprotective agent, noting observed activity across neurochemical signalling pathways in preclinical data.
The peptide is notably acid-stable — it does not lose bioactivity in gastric conditions — distinguishing it from most peptide compounds and making oral delivery a subject of ongoing research interest.